Zealand announces amendments to its Articles of Association

        Print
| Source: Zealand Pharma A/S
multilang-release

Copenhagen, 2013-05-08 14:30 CEST (GLOBE NEWSWIRE) -- Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that the company’s Articles of Association have been amended.

The amendments to the Articles of Association are entailed by the decision at the company’s Annual General Meeting, held on 30 April 2013 to establish a Shareholder Nomination Committee. The purpose of this committee is to assess the composition of the Board of Directors and to present recommendations to the General Meeting about the board members up for election at the general meeting. In accordance with this decision, it was decided also at the meeting to incorporate a new Article 15 into the company’s Articles of Association.

The amended Articles of Association including a new Article 15 have today been registered with the Danish Commerce Agency. The new Articles of Association are attached to this announcement and are also available on Zealand’s website; www.zealandpharma.com.

The Rules of Procedure for a Shareholder Nomination Committee are also available on the website.

  

***

  

For further information, please contact:

 

David Solomon, President and Chief Executive Officer

Tel: +45 22 20 63 00

 

Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate Communication

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

 

About Zealand

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide, a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is approved in Europe (February 2013) under the name of Lyxumia®, and under regulatory review in a large number of other countries globally, including in the US (NDA filed in Dec 2012) and Japan (NDA filed in June 2012).

 

Zealand has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury. For further information: www.zealandpharma.com